{"entity":{"id":"nct00004054","kind":"trial","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Bicalutamide, Estramustine, Etoposide, Flutamide and Paclitaxel / nab-paclitaxel in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","summary":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00004054 by Radiation Therapy Oncology Group, with 397 participants recorded, started 2000-01 and reaching its primary completion in 2010-04. Interventions recorded: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Estramustine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00004054","url":"https://clinicaltrials.gov/study/NCT00004054"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["bicalutamide","estramustine","etoposide","flutamide","paclitaxel"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00004054","phase":"3","setting":"A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer","sponsor":"Radiation Therapy Oncology Group","started":"2000-01","yearReported":2015,"enrolled":397,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (5-year Rate Reported)","primary":true,"unit":"%","arms":[{"name":"Hormones and RT","n":197,"value":84.9,"note":"95% CI 79.9 to 90; Figures from the ClinicalTrials.gov results section (first posted 2015-01-07), not from a publication"},{"name":"Hormones and RT Plus Chemotherapy","n":200,"value":87.2,"note":"95% CI 82.4 to 91.9"}],"hr":1.04,"ci":[0.76,1.43],"p":"0.81","source":"https://clinicaltrials.gov/study/NCT00004054?tab=results"}]},"route":"/trials/nct00004054/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/"},{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}]}}